Ritedose Launches Critical Single-Dose Syringe Product Amid National Drug Shortage: <em>Lidocaine Hydrochloride 1% 100 mg/10 mL</em>

COLUMBIA, S.C. (October 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Lidocaine Hydrochloride 1% 100 mg/10 mL. It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation,

Continue reading

Ritedose Reaches Milestone with Asset Purchase <br><em>Becomes largest generic drug maker of its kind</em>

COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.

Continue reading